Novo sues Hims & Hers despite Wegovy pill offering U-turn
Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.
Therapy Area
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
Corxel raises $287m as obesity continues to spark investor interest
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
J&J’s Caplyta doubles remission rate in MDD patients
JPM26: Enanta outlines strategy to lead in RSV therapeutics
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
